Cargando…

Heat shock factor 1 confers resistance to lapatinib in ERBB2-positive breast cancer cells

Despite success of ERBB2-targeted therapies such as lapatinib, resistance remains a major clinical concern. Multiple compensatory receptor tyrosine kinase (RTK) pathways are known to contribute to lapatinib resistance. The heterogeneity of these adaptive responses is a significant hurdle for finding...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yallowitz, Alisha, Ghaleb, Amr, Garcia, Lucas, Alexandrova, Evguenia M., Marchenko, Natalia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5967334/ https://www.ncbi.nlm.nih.gov/pubmed/29799521 http://dx.doi.org/10.1038/s41419-018-0691-x

Ejemplares similares

Irradiation induces p53 loss of heterozygosity in breast cancer expressing mutant p53
por: Ghaleb, Amr, et al.
Publicado: (2019)

Mutant p53 – Heat Shock Response Oncogenic Cooperation: A New Mechanism of Cancer Cell Survival
por: Alexandrova, Evguenia M., et al.
Publicado: (2015)

ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells
por: Li, Dun, et al.
Publicado: (2016)

Tyrosine Phosphatase PTPRO Deficiency in ERBB2-Positive Breast Cancer Contributes to Poor Prognosis and Lapatinib Resistance
por: Dong, Hongmei, et al.
Publicado: (2022)

Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
por: Kaufman, Bella, et al.
Publicado: (2008)

ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression
por: Qi, Leilei, et al.
Publicado: (2017)

Management of ErbB2-positive Breast Cancer: Insights from Preclinical and Clinical Studies with Lapatinib
por: Vogel, Charles, et al.
Publicado: (2010)

An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway
por: Yang, Zi-Yan, et al.
Publicado: (2020)

The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells
por: Komurov, Kakajan, et al.
Publicado: (2012)

Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells
por: Ghaleb, Amr, et al.
Publicado: (2020)

Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2
por: Karakashev, Sergey V., et al.
Publicado: (2015)

Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib
por: Kancha, Rama Krishna, et al.
Publicado: (2011)

The HSP-RTK-Akt axis mediates acquired resistance to Ganetespib in HER2-positive breast cancer
por: Eyermann, Christopher E., et al.
Publicado: (2021)

t-Darpp overexpression in HER2-positive breast cancer confers a survival advantage in lapatinib
por: Christenson, Jessica L., et al.
Publicado: (2015)

HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3
por: Chen, Jhen-Yu, et al.
Publicado: (2015)

Role of ErbB1 in the Underlying Mechanism of Lapatinib-Induced Diarrhoea: A Review
por: Raja Sharin, Raja Nur Firzanah Syaza, et al.
Publicado: (2022)

Src Mutation Induces Acquired Lapatinib Resistance in ERBB2-Amplified Human Gastroesophageal Adenocarcinoma Models
por: Hong, Yong Sang, et al.
Publicado: (2014)

Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem
por: Wahdan-Alaswad, Reema, et al.
Publicado: (2020)

p63 suppresses the ability of pregnancy-identified mammary epithelial cells (PIMECs) to drive HER2-positive breast cancer
por: Eyermann, Christopher E., et al.
Publicado: (2021)

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells
por: Ye, Min, et al.
Publicado: (2021)

Correction: p63 suppresses the ability of pregnancy-identified mammary epithelial cells (PIMECs) to drive HER2-positive breast cancer
por: Eyermann, Christopher E., et al.
Publicado: (2021)

Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice
por: Ma, Zhikun, et al.
Publicado: (2017)

p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo
por: Alexandrova, Evguenia M, et al.
Publicado: (2017)

miR‐221 confers lapatinib resistance by negatively regulating p27(kip1) in HER2‐positive breast cancer
por: Huynh, Thanh Kieu, et al.
Publicado: (2021)

The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells
por: Lyu, Hui, et al.
Publicado: (2015)

A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer
por: Janni, Wolfgang, et al.
Publicado: (2014)

HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line
por: Lee, Hye Jin, et al.
Publicado: (2020)

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience
por: Sutherland, S, et al.
Publicado: (2010)

Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
por: Yuan, Ye, et al.
Publicado: (2022)

A gain-of-function mutant p53–HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stress
por: Li, D, et al.
Publicado: (2014)

Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer
por: Leung, Wing-yin, et al.
Publicado: (2015)

Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer
por: Agelaki, Sofia, et al.
Publicado: (2015)

Efficacy and Tolerability of Lapatinib in the Management of Breast Cancer
por: Rana, Punam, et al.
Publicado: (2012)

Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients
por: Duchnowska, Renata, et al.
Publicado: (2015)

Real‐world data of lapatinib and treatment after lapatinib in patients with previously treated HER2‐positive metastatic breast cancer: A multicenter, retrospective study
por: Xie, Yizhao, et al.
Publicado: (2020)

Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2017)

The natural compound fucoidan from New Zealand Undaria pinnatifida synergizes with the ERBB inhibitor lapatinib enhancing melanoma growth inhibition
por: Thakur, Varsha, et al.
Publicado: (2017)

Cholesterol content in cell membrane maintains surface levels of ErbB2 and confers a therapeutic vulnerability in ErbB2-positive breast cancer
por: Zhang, Jinrui, et al.
Publicado: (2019)

Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells
por: Kaczyńska, Angelika, et al.
Publicado: (2016)

Dynamic ultrasound molecular‐targeted imaging of senescence in evaluation of lapatinib resistance in HER2‐positive breast cancer
por: Chen, Xiaoyu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l2njumcg6cdh7lqpqc6af2rd1h